The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform
Nobuaki Honda - One of the best experts on this subject based on the ideXlab platform.
-
Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary Superficial Bladder Cancer.
Oncology reports, 2006Co-Authors: Shigeyuki Aoki, Yoshiaki Yamada, Kogenta Nakamura, Tomohiro Taki, Motoi Tobiume, Nobuaki HondaAbstract:No prognostic marker for predicting recurrence in primary Superficial Bladder Cancer has been established. The aim of this study was to investigate the expression levels of thymidine phosphorylase (TP) by enzyme-linked immunosorbent assay (ELISA) and the immunohistological localization of TP in primary Superficial Bladder Cancer tissue to assess its association with tumor recurrence and stage progression as well as the pathological parameters of the tumor. TP expression in Cancer tissues from 77 patients was measured by sandwich-type ELISA. Clinicopathological factors and the clinical prognosis were examined in relation to the expression levels of TP. To clarify the clinicopathological implication of TP localization in primary Superficial Bladder Cancer tissue, the immunohistochemically determined TP expression was assessed for histological grades 1-3. The TP expression in primary Superficial Bladder Cancer significantly increased with the histological grade and stage. The TP expression in patients with a shift to invasive Cancer was significantly higher than in those without invasive Cancer. Patients with low TP expression had a significant longer postoperative tumor-free period than those with high TP expression (P=0.011). High TP expression was an independent prognostic factor for tumor recurrence (P=0.0441). Strong immunoreactivity for TP was observed in the cytoplasms of tumor cells and vascular endothelial cells. This study suggests that elevated TP expression may be a prognostic marker for predicting recurrence in primary Superficial Bladder Cancer, and that high TP expression may be associated with the marked proliferation of tumor cells and increased vascular endothelial cells, showing strong immunoreactivity for TP.
Frans M.j. Debruyne - One of the best experts on this subject based on the ideXlab platform.
-
Intravesical chemotherapy for Superficial Bladder Cancer.
Nature clinical practice. Urology, 2004Co-Authors: J.a. Witjes, Frans M.j. DebruyneAbstract:Witjes and Debruyne outline how recent investigations of indications for intravesical chemotherapy might affect current strategies for the management of Superficial Bladder Cancer. Recommendations for the use of chemotherapeutics are made on the basis of the risk of recurrence and progression of this increasingly common disease.
-
Bacillus Calmette-Guérin in Superficial Bladder Cancer: consensus and controversies.
European urology, 1995Co-Authors: P. D. J. Vegt, Frans M.j. Debruyne, A. P. M. Van Der MeijdenAbstract:In this overview, Bacillus Calmette-Guerin (BCG) immunotherapy in Superficial Bladder Cancer items are discussed on which consensus has been reached and on which controversies exist. The evaluation of the optimal route of administration has shown that intravesical instillation of BCG alone is accepted as the best route of administration. In searching for the appropriate BCG strain, the analysis of the results of 6 substrains has made clear that no particular strain has shown superiority over others. In finding the optimal treatment schedule there is strong evidence that maintenance therapy is superior to induction therapy alone. No consensus has been reached about the optimal dose for BCG therapy nor about how the toxicity of BCG treatment can be reduced. Although some reports have stated that BCG immunotherapy is superior to chemotherapy for the treatment of patients with Superficial Bladder Cancer, more data are needed to prove this statement. In conclusion, although BCG has been proven to be very effective in the treatment of patients with Superficial Bladder Cancer, it is certainly not a panacea for all patients with Superficial Bladder Cancer.
-
Intravesical therapy in Superficial Bladder Cancer.
Urology, 1994Co-Authors: J.a. Witjes, Peter F.a. Mulders, Frans M.j. DebruyneAbstract:Abstract Objective . To identify the appropriate characteristics of Superficial Bladder Cancer that allow the physician to predict tumor behavior. Methods . We analyzed 1,745 patients with primary Superficial Bladder Cancer with regard to disease and patient characteristics. Results . With the characteristics we found, the population can be described and prognostic factors can be found. Moreover, with the use of these factors, it appears to be possible to predict tumor behavior on a group level. Prediction on an individual level, however, remains far from ideal. Conclusions . Three treatment options can be chosen: follow-up after initial transurethral resection, additional instillations with intravesical chemotherapy, or instillations with bacillus Calmette-Guerin (BCG). In case instillations are indicated, most (but not all) Superficial Bladder Cancer trials show superiority of BCG over intravesical chemotherapy, although at the cost of more side effects. However, with intravesical BCG, it seems possible to influence the natural history of Superficial Bladder Cancer, which means that we can delay progression and improve survival.
-
Intravesical therapy in Superficial Bladder Cancer. Commentary
Urology, 1994Co-Authors: J.a. Witjes, Peter F.a. Mulders, Frans M.j. Debruyne, H. Barton GrossmanAbstract:Objective. To identify the appropriate characteristics of Superficial Bladder Cancer that allow the physician to predict tumor behavior. Methods. We analyzed 1,745 patients with primary Superficial Bladder Cancer with regard to disease and patient characteristics. Results. With the characteristics we found, the population can be described and prognostic factors can be found. Moreover, with the use of these factors, it appears to be possible to predict tumor behavior on a group level. Prediction on an individual level, however, remains far from ideal. Conclusions. Three treatment options can be chosen: follow-up after initial transurethral resection, additional instillations with intravesical chemotherapy, or instillations with bacillus Calmette-Guerin (BCG)
Marc Colombel - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic factors in Superficial Bladder Cancer.
World journal of urology, 1993Co-Authors: D. K. Chopin, Zivko Popov, Vincent Ravery, J. Bellot, A. Hoznek, Jean Jacques Patard, C.c. Abbou, Marc ColombelAbstract:A large body of evidence suggests that intravescial prophylaxis using vacilus Calmette-Guerin can favorably alter the natural history of Superficial Bladder Cancer. The search for prognostic factors impacting the clinical alternative between conservative and radical treatment has been the subject of numerous efforts and remains a major objective in improving the carcinological results and the quality of life patients with Superficial Bladder Cancer. In this regard, information is available on three levels: clinicopathological parameters, quantitative analysis, and biological markers. Recent advances in as well as the limitations and pitfalls of the use of three kinds of information in prognostication are reviewed. The proper use of prognostic factors will modify our attitude toward Superficial Bladder Cancer in the near future.
Stephen J. Freedland - One of the best experts on this subject based on the ideXlab platform.
-
Does Treatment Intensity Matter in Superficial Bladder Cancer? Consensus, Clinical Practice, and Confounding
Journal of the National Cancer Institute, 2009Co-Authors: Gary H. Lyman, Nicole M. Kuderer, Stephen J. FreedlandAbstract:The majority of patients who are diagnosed with Bladder Cancer initially present with noninvasive disease (1). Nevertheless, 40%–80% of patients diagnosed with Superficial Bladder Cancers will experience a recurrence, including 10%–25% of those with potentially lethal muscle-invasive disease, within the first 3 years after diagnosis (2–4). Current guidelines from the American Urologic Association (5,6) and the National Comprehensive Cancer Network (5,6) recommend frequent cystoscopic surveillance of patients diagnosed with Superficial Bladder Cancer. However, physicians treating patients with Superficial Bladder Cancer vary widely in their adherence to surveillance guidelines (7). Practical and ethical considerations that preclude randomized controlled trials to establish the impact of surveillance on survival of patients with Superficial Bladder Cancer include the high recurrence rate, the ability of cystoscopic surveillance to identify recurrence early, the demonstrated efficacy of local therapy in preventing or delaying the development of muscle-invasive disease, and the overall poor prognosis of muscle-invasive disease (7–10).
Shigeyuki Aoki - One of the best experts on this subject based on the ideXlab platform.
-
Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary Superficial Bladder Cancer.
Oncology reports, 2006Co-Authors: Shigeyuki Aoki, Yoshiaki Yamada, Kogenta Nakamura, Tomohiro Taki, Motoi Tobiume, Nobuaki HondaAbstract:No prognostic marker for predicting recurrence in primary Superficial Bladder Cancer has been established. The aim of this study was to investigate the expression levels of thymidine phosphorylase (TP) by enzyme-linked immunosorbent assay (ELISA) and the immunohistological localization of TP in primary Superficial Bladder Cancer tissue to assess its association with tumor recurrence and stage progression as well as the pathological parameters of the tumor. TP expression in Cancer tissues from 77 patients was measured by sandwich-type ELISA. Clinicopathological factors and the clinical prognosis were examined in relation to the expression levels of TP. To clarify the clinicopathological implication of TP localization in primary Superficial Bladder Cancer tissue, the immunohistochemically determined TP expression was assessed for histological grades 1-3. The TP expression in primary Superficial Bladder Cancer significantly increased with the histological grade and stage. The TP expression in patients with a shift to invasive Cancer was significantly higher than in those without invasive Cancer. Patients with low TP expression had a significant longer postoperative tumor-free period than those with high TP expression (P=0.011). High TP expression was an independent prognostic factor for tumor recurrence (P=0.0441). Strong immunoreactivity for TP was observed in the cytoplasms of tumor cells and vascular endothelial cells. This study suggests that elevated TP expression may be a prognostic marker for predicting recurrence in primary Superficial Bladder Cancer, and that high TP expression may be associated with the marked proliferation of tumor cells and increased vascular endothelial cells, showing strong immunoreactivity for TP.
